Video:La Crosse encephalitis

From WikiProjectMed
Jump to navigation Jump to search
La Crosse encephalitis (Tutorial)
Commons / NC
Steps for video creation
Step 1Preview my changes (10 sec)
Step 2Upload to Commons (10 min)

Edit with VisualEditor

Description

La Crosse encephalitis is an encephalitis caused by an arbovirus, the La Crosse virus, which has a mosquito vector (Ochlerotatus triseriatus).[1] Symptoms include fever and headache, while there is no established treatment.[2]

Presentation

Symptoms include nausea, headache, vomiting in milder cases and seizures, coma, paralysis and permanent brain damage in severe cases.[2][3][4]

Cause

The La Crosse encephalitis virus is a type of arbovirus called a bunyavirus,[5] the Bunyavirales are mainly arboviruses. LAC virus is a zoonotic pathogen cycled between the daytime-biting treehole mosquito, Aedes triseriatus, and vertebrate amplifier hosts in deciduous forest habitats. [6][2]

Diagnosis

The diagnosis of La Crosse encephalitis is done via the following procedures which are , blood test, spinal fluid test and EEG (to detect seizures).[7]

Differential diagnosis

The differential diagnosis for La Crosse encephalitis is as follows,Wernickes encephalitis, focal seizures, Cryptococcal meningitis and Herpes simplex virus encephalitis.[2]

Treatment

No specific therapy is available at present for La Crosse encephalitis, and management is limited to alleviating the symptoms and balancing fluids and electrolyte levels. [8]

Epidemiology

La Crosse encephalitis was discovered in 1965, after the virus was isolated from stored brain and spinal tissue of a child who died of an unknown infection in La Crosse, Wisconsin in 1960.[9] It occurs in the Appalachian and Midwestern regions of the United States. Recently there has been an increase of cases in the South East of the United States. [10][11]

Research

Intravenous ribavirin is effective against La Crosse encephalitis virus in the laboratory, additionally several studies in individuals with severe, La Crosse encephalitis are ongoing.[12][13]

References

  1. McJunkin, J. E.; de los Reyes, E. C.; Irazuzta, J. E.; Caceres, M. J.; Khan, R. R.; Minnich, L. L.; Fu, K. D.; Lovett, G. D.; Tsai, T.; Thompson, A. (March 2001). "La Crosse Encephalitis in Children". The New England Journal of Medicine. 344 (11): 801–7. doi:10.1056/NEJM200103153441103. PMID 11248155.
  2. 2.0 2.1 2.2 2.3 Khan, Usaamah M.; Gudlavalleti, Aashrai (2024). "La Crosse Encephalitis". StatPearls. StatPearls Publishing.
  3. "Symptoms, Diagnosis, & Treatment | La Crosse encephalitis | CDC". www.cdc.gov. 7 November 2022. Archived from the original on 20 October 2022. Retrieved 2 April 2023.
  4. "La Crosse encephalitis - About the Disease - Genetic and Rare Diseases Information Center". rarediseases.info.nih.gov. Archived from the original on 18 May 2022. Retrieved 4 April 2023.
  5. Center for Disease Control and Prevention (CDC) (January 2009). "Possible Congenital Infection with La Crosse Encephalitis Virus — West Virginia, 2006–2007". MMWR. Morbidity and Mortality Weekly Report. 58 (1): 4–7. PMID 19145220. Archived from the original on 2019-09-29. Retrieved 2021-09-10.
  6. McJunkin, J. E.; Khan, R. R.; Tsai, T. F. (March 1998). "California-La Crosse encephalitis". Infectious Disease Clinics of North America. 12 (1): 83–93. doi:10.1016/s0891-5520(05)70410-4. ISSN 0891-5520. Archived from the original on 4 April 2023. Retrieved 5 April 2023.
  7. "Frequently Asked Questions | La Crosse encephalitis | CDC". www.cdc.gov. 7 January 2022. Archived from the original on 25 January 2022. Retrieved 24 January 2022.
  8. "La Crosse encephalitis". CDC. Retrieved 1 July 2024.
  9. Thompson, W.H.; Kalfayan, B.; Anslow, R.O. (1965). "Isolation of California encephalitis virus from a fatal human illness". Am. J. Epidemiol. 81 (2): 245–253. doi:10.1093/oxfordjournals.aje.a120512. PMID 14261030.
  10. Bewick, Sharon; Agusto, Folashade; Calabrese, Justin M.; Muturi, Ephantus J.; Fagan, William F. (November 2016). "Epidemiology of La Crosse Virus Emergence, Appalachia Region, United States". Emerging Infectious Diseases. 22 (11): 1921–1929. doi:10.3201/eid2211.160308. ISSN 1080-6059. Archived from the original on 2022-06-20. Retrieved 2023-04-03.
  11. Rowe, R. D.; Odoi, A.; Paulsen, D.; Moncayo, A. C.; Trout Fryxell, R. T. (3 September 2020). "Spatial-temporal clusters of host-seeking Aedes albopictus, Aedes japonicus, and Aedes triseriatus collections in a La Crosse virus endemic county (Knox County, Tennessee, USA)". PLOS ONE. 15 (9): e0237322. doi:10.1371/journal.pone.0237322. Archived from the original on 13 April 2023. Retrieved 13 April 2023.
  12. Haddow, Andrew D.; Haddow, Alastair D. (February 2009). "The use of oral ribavirin in the management of La Crosse viral infections". Medical Hypotheses. 72 (2): 190–192. doi:10.1016/j.mehy.2008.05.043. ISSN 0306-9877. Archived from the original on 1 April 2023. Retrieved 8 April 2023.
  13. McJunkin, J. E.; Khan, R.; de los Reyes, E. C.; Parsons, D. L.; Minnich, L. L.; Ashley, R. G.; Tsai, T. F. (February 1997). "Treatment of severe La Crosse encephalitis with intravenous ribavirin following diagnosis by brain biopsy". Pediatrics. 99 (2): 261–267. doi:10.1542/peds.99.2.261. ISSN 1098-4275. Archived from the original on 2023-04-01. Retrieved 2023-04-09.